Biomarkers of Cartilage and Surrounding Joint Tissue

References

• Karsdal MA , HenriksenK, LeemingDJet al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14 (3), 181 – 202 (2009).
   PubMed Web of Science ®Google Scholar
• Frank R , HargreavesR. Clinical biomarkers in drug discovery and development.Nat. Rev. Drug Discov.2 (7), 566 – 580 (2003).
   PubMed Web of Science ®Google Scholar
• James CB , UhlTL. A review of articular cartilage pathology and the use of glucosamine sulfate.J. Athl. Train.36 (4), 413 – 419 (2001).
   PubMed Web of Science ®Google Scholar
• Goldring MB , MarcuKB. Cartilage homeostasis in health and rheumatic diseases.Arthritis Res. Ther.11 (3), 224 (2009).
   PubMed Web of Science ®Google Scholar
• Fosang AJ , BeierF. Emerging Frontiers in cartilage and chondrocyte biology.Best Pract. Res. Clin. Rheumatol.25 (6), 751 – 766 (2011).
   PubMed Web of Science ®Google Scholar
• Hosseininia S , LindbergLR, DahlbergLE. Cartilage collagen damage in hip osteoarthritis similar to that seen in knee osteoarthritis; a case–control study of relationship between collagen, glycosaminoglycan and cartilage swelling.BMC Musculoskelet. Disord.14, 18 (2013).
   PubMedGoogle Scholar
• Beier F . Cell-cycle control and the cartilage growth plate.J. Cell. Physiol.202 (1), 1 – 8 (2005).
   PubMed Web of Science ®Google Scholar
• Aigner T , ReichenbergerE, BertlingW, KirschT, StossH, von derMK. Type X collagen expression in osteoarthritic and rheumatoid articular cartilage.Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol.63 (4), 205 – 211 (1993).
   PubMedGoogle Scholar
• Chung UI . Essential role of hypertrophic chondrocytes in endochondral bone development.Endocr. J.51 (1), 19 – 24 (2004).
   PubMed Web of Science ®Google Scholar
• Bay-Jensen AC , Hoegh-MadsenS, DamEet al. Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Rheumatol. Int. 30 (4), 435 – 442 (2010).
   PubMed Web of Science ®Google Scholar
• Sims NA , GooiJH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption.Semin. Cell Dev. Biol.19 (5), 444 – 451 (2008).
   PubMed Web of Science ®Google Scholar
• Manolagas SC . Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.Endocr. Rev.21 (2), 115 – 137 (2000).
   PubMed Web of Science ®Google Scholar
• Henriksen K , Neutzsky-WulffAV, BonewaldLF, KarsdalMA. Local communication on and within bone controls bone remodeling.Bone44 (6), 1026 – 1033 (2009).
   PubMed Web of Science ®Google Scholar
• Eriksen EF . Cellular mechanisms of bone remodeling.Rev. Endocr. Metab. Disord.11 (4), 219 – 227 (2010).
   PubMed Web of Science ®Google Scholar
• Nakahama K . Cellular communications in bone homeostasis and repair.Cell Mol. Life Sci.67 (23), 4001 – 4009 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen MM Jr . The new bone biology: pathologic, molecular, and clinical correlates.Am. J. Med. Genet. A140 (23), 2646 – 2706 (2006).
   PubMed Web of Science ®Google Scholar
• Matsuo K . Cross-talk among bone cells.Curr. Opin. Nephrol. Hypertens.18 (4), 292 – 297 (2009).
   PubMed Web of Science ®Google Scholar
• Barger-Lux MJ , ReckerRR. Bone microstructure in osteoporosis: transilial biopsy and histomorphometry.Top. Magn. Reson. Imaging13 (5), 297 – 305 (2002).
   PubMedGoogle Scholar
• Clarke B . Normal bone anatomy and physiology.Clin. J. Am. Soc. Nephrol.3 (Suppl. 3), S131 – S139 (2008).
   PubMed Web of Science ®Google Scholar
• Theill LE , BoyleWJ, PenningerJM. RANK-L and RANK: T cells, bone loss, and mammalian evolution.Annu. Rev. Immunol.20, 795 – 823 (2002).
   PubMed Web of Science ®Google Scholar
• Yasuda H , ShimaN, NakagawaNet al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95 (7), 3597 – 3602 (1998).
   PubMed Web of Science ®Google Scholar
• Suda T , TakahashiN, UdagawaN, JimiE, GillespieMT, MartinTJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.Endocr. Rev.20 (3), 345 – 357 (1999).
   PubMed Web of Science ®Google Scholar
• Mizuno A , AmizukaN, IrieKet al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247 (3), 610 – 615 (1998).
   PubMed Web of Science ®Google Scholar
• Bucay N , SarosiI, DunstanCRet al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (9), 1260 – 1268 (1998).
   PubMed Web of Science ®Google Scholar
• Trouvin AP , GoebV. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.Clin. Interv. Aging5, 345 – 354 (2010).
   PubMed Web of Science ®Google Scholar
• den UD , BultinkIE, LemsWF. Advances in glucocorticoid-induced osteoporosis.Curr. Rheumatol. Rep.13 (3), 233 – 240 (2011).
   PubMed Web of Science ®Google Scholar
• Khosla S . Update on estrogens and the skeleton.J. Clin. Endocrinol. Metab.95 (8), 3569 – 3577 (2010).
   PubMed Web of Science ®Google Scholar
• Seeman E . Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.Osteoporos. Int.14 (Suppl. 3), S2 – S8 (2003).
   PubMedGoogle Scholar
• Maruotti N , d’OnofrioF, CorradoA, CantatoreFP. Why TNF-alpha inhibition is not sufficient to avoid juxta-articular erosions in chronic arthritis?Intern. Emerg. Med.7 (1), 15 – 20 (2012).
   PubMed Web of Science ®Google Scholar
• Lee JJ , AghdassiE, CheungAMet al. Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. J. Rheumatol. 39 (7), 1378 – 1384 (2012).
   PubMed Web of Science ®Google Scholar
• Kim HJ , HongSJ, JeonYWet al. The early onset of disease may be a risk factor for decreased bone mineral density in patients with inflammatory bowel disease. Clin. Endosc. 46 (1), 71 – 76 (2013).
   PubMedGoogle Scholar
• Ciacli C , CojocaruM. Systemic osteoporosis – major complication of psoriatic arthritis.Rom. J. Intern. Med.50 (2), 173 – 178 (2012).
   PubMedGoogle Scholar
• Burr DB , GallantMA. Bone remodelling in osteoarthritis.Nat. Rev. Rheumatol.8 (11), 665 – 673 (2012).
   PubMed Web of Science ®Google Scholar
• Burr DB . The importance of subchondral bone in the progression of osteoarthritis.J. Rheumatol. Suppl.70, 77 – 80 (2004).
   PubMedGoogle Scholar
• Smith MD . The normal synovium.Open Rheumatol. J.5, 100 – 106 (2011).
   PubMedGoogle Scholar
• Fox DB , WarnockJJ. Cell-based meniscal tissue engineering: a case for synoviocytes.Clin. Orthop. Relat. Res.469 (10), 2806 – 2816 (2011).
   PubMed Web of Science ®Google Scholar
• Scanzello CR , GoldringSR. The role of synovitis in osteoarthritis pathogenesis.Bone51 (2), 249 – 257 (2012).
   PubMed Web of Science ®Google Scholar
• Noss EH , BrennerMB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis.Immunol. Rev.223, 252 – 270 (2008).
   PubMed Web of Science ®Google Scholar
• de Lange-Brokaar BJ , Ioan-FacsinayA, van OschGJet al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage 20 (12), 1484 – 1499 (2012).
   PubMed Web of Science ®Google Scholar
• Firestein GS , varo-GraciaJM, MakiR. Quantitative analysis of cytokine gene expression in rheumatoid arthritis.J. Immunol.144 (9), 3347 – 3353 (1990).
   PubMed Web of Science ®Google Scholar
• Bottini N , FiresteinGS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors.Nat. Rev. Rheumatol.9 (1), 24 – 33 (2013).
   PubMed Web of Science ®Google Scholar
• Tolboom TC , PietermanE, van der LaanWHet al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann. Rheum. Dis. 61 (11), 975 – 980 (2002).
   PubMed Web of Science ®Google Scholar
• Haywood L , McWilliamsDF, PearsonCIet al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum. 48 (8), 2173 – 2177 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue K , Masuko-HongoK, OkamotoM, NishiokaK. Induction of vascular endothelial growth factor and matrix metalloproteinase-3 (stromelysin) by interleukin-1 in human articular chondrocytes and synoviocytes.Rheumatol. Int.26 (2), 93 – 98 (2005).
   PubMed Web of Science ®Google Scholar
• Karsdal MA , DelvinE, ChristiansenC. Protein fingerprints – relying on and understanding the information of serological protein measurements.Clin. Biochem.44 (16), 1278 – 1279 (2011).
   PubMed Web of Science ®Google Scholar
• Rosenquist C , FledeliusC, ChristgauSet al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 44 (11), 2281 – 2289 (1998).
   PubMed Web of Science ®Google Scholar
• Ravn P , HoskingD, ThompsonDet al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J. Clin. Endocrinol. Metab. 84 (7), 2363 – 2368 (1999).
   PubMed Web of Science ®Google Scholar
• Ravn P , ClemmesenB, ChristiansenC. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.Bone24 (3), 237 – 244 (1999).
   PubMed Web of Science ®Google Scholar
• Ravn P , ThompsonDE, RossPD, ChristiansenC. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.Bone33 (1), 150 – 158 (2003).
   PubMed Web of Science ®Google Scholar
• Hanson DA , WeisMA, BollenAM, MaslanSL, SingerFR, EyreDR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.J. Bone Miner. Res.7 (11), 1251 – 1258 (1992).
   PubMed Web of Science ®Google Scholar
• Garnero P , FerrerasM, KarsdalMAet al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J. Bone Miner. Res. 18 (5), 859 – 867 (2003).
   PubMed Web of Science ®Google Scholar
• Kato S , EndoI, FujimuraMet al. Serum carboxy-terminal telopeptide of type I collagen (ICTP) as a surrogate marker for vulnerable plaques in atherosclerotic patients: a pilot study. Atherosclerosis 229 (1), 182 – 185 (2013).
   PubMed Web of Science ®Google Scholar
• Leeming D , HeY, VeidalSet al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16 (7), 616 – 628 (2011).
   PubMed Web of Science ®Google Scholar
• Veidal SS , VassiliadisE, Bay-JensenAC, TougasG, VainerB, KarsdalMA. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats.Fibrogenesis Tissue Repair3 (1), 5 (2010).
   PubMedGoogle Scholar
• Garnero P , AyralX, RousseauJCet al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 46 (10), 2613 – 2624 (2002).
   PubMed Web of Science ®Google Scholar
• Rousseau JC , ZhuY, MiossecPet al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 12 (6), 440 – 447 (2004).
   PubMed Web of Science ®Google Scholar
• Sharif M , KirwanJ, CharniN, SandellLJ, WhittlesC, GarneroP. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis – association with disease progression.Rheumatology (Oxf.)46 (6), 938 – 943 (2007).
   PubMed Web of Science ®Google Scholar
• Madsen SH , SondergaardBC, Bay-JensenAC, KarsdalMA. Cartilage formation measured by a novel PIINP assay suggests that IGF-I does not stimulate but maintains cartilage formation ex vivo.Scand. J. Rheumatol.38 (3), 222 – 226 (2009).
   PubMed Web of Science ®Google Scholar
• Olsen AK , SondergaardBC, ByrjalsenIet al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 15 (3), 335 – 342 (2007).
   PubMed Web of Science ®Google Scholar
• Shinmei M , ItoK, MatsuyamaS, YoshiharaY, MatsuzawaK. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis.Osteoarthritis Cartilage1 (2), 121 – 128 (1993).
   PubMedGoogle Scholar
• Sugiyama S , ItokazuM, SuzukiY, ShimizuK. ProcollagenII C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann. Rheum. Dis. 62 (1), 27 – 32 (2003).
   PubMed Web of Science ®Google Scholar
• Lohmander LS , YoshiharaY, RoosH, KobayashiT, YamadaH, ShinmeiM. Procollagen IIC-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis.J. Rheumatol.23 (10), 1765 – 1769 (1996).
   PubMed Web of Science ®Google Scholar
• Downs JT , LaneCL, NestorNBet al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J. Immunol. Methods 247 (1–2), 25 – 34 (2001).
   PubMed Web of Science ®Google Scholar
• Christgau S , GarneroP, FledeliusCet al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29 (3), 209 – 215 (2001).
   PubMed Web of Science ®Google Scholar
• Garnero P , CharniN, JuilletF, ConrozierT, VignonE. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis.Ann. Rheum. Dis.65 (12), 1639 – 1644 (2006).
   PubMed Web of Science ®Google Scholar
• van Spil WE , Drossaers-BakkerKW, LafeberFP. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis.Ann. Rheum. Dis.72 (1), 29 – 36 (2013).
   PubMed Web of Science ®Google Scholar
• Lohmander LS , AtleyLM, PietkaTA, EyreDR. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis.Arthritis Rheum.48 (11), 3130 – 3139 (2003).
   PubMedGoogle Scholar
• Hellio Le Graverand MP , BrandtKDet al. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 14 (11), 1189 – 1195 (2006).
   PubMed Web of Science ®Google Scholar
• Nemirovskiy OV , DufieldDR, SunyerT, AggarwalP, WelschDJ, MathewsWR. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo.Anal. Biochem.361 (1), 93 – 101 (2007).
   PubMed Web of Science ®Google Scholar
• Charni N , JuilletF, GarneroP. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.Arthritis Rheum.52 (4), 1081 – 1090 (2005).
   PubMedGoogle Scholar
• Eyre DR , WeisMA. The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence.Osteoarthritis Cartilage17 (4), 423 – 426 (2009).
   PubMed Web of Science ®Google Scholar
• Bay-Jensen AC , LiuQ, ByrjalsenIet al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM – increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin. Biochem. 44 (5–6): 423 – 429 (2011).
   PubMed Web of Science ®Google Scholar
• Henrotin Y , DebergM, DubucJE, QuettierE, ChristgauS, ReginsterJY. Type II collagen peptides for measuring cartilage degradation.Biorheology41 (3–4): 543 – 547 (2004).
   PubMed Web of Science ®Google Scholar
• Deberg M , LabasseA, ChristgauSet al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13 (3), 258 – 265 (2005).
   PubMed Web of Science ®Google Scholar
• Deberg MA , LabasseAH, ColletteJ, SeidelL, ReginsterJY, HenrotinYE. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression.Osteoarthritis Cartilage13 (12), 1059 – 1065 (2005).
   PubMed Web of Science ®Google Scholar
• Ameye LG , DebergM, OliveiraM, LabasseA, AeschlimannJM, HenrotinY. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice.Arthritis Rheum.56 (10), 3336 – 3346 (2007).
   PubMedGoogle Scholar
• Henrotin Y , ChevalierX, DebergMet al. Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO(2)) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. J. Orthop. Res. 31 (6), 901 – 907 (2013).
   PubMed Web of Science ®Google Scholar
• Poole AR , IonescuM, FitzcharlesMA, BillinghurstRC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases.J. Immunol. Methods294 (1–2), 145 – 153 (2004).
   PubMed Web of Science ®Google Scholar
• Billinghurst RC , MwaleF, HollanderA, IonescuM, PooleAR. Immunoassays for collagens in chondrocyte and cartilage explant cultures.Methods Mol. Med.100, 251 – 274 (2004).
   PubMedGoogle Scholar
• Billinghurst RC , DahlbergL, IonescuMet al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 99 (7), 1534 – 1545 (1997).
   PubMed Web of Science ®Google Scholar
• Barascuk N , VeidalSS, LarsenLet al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin. Biochem. 43 (10–11), 899 – 904 (2010).
   PubMed Web of Science ®Google Scholar
• Risteli J , NiemiS, TrivediP, MaentaustaO, MowatAP, RisteliL. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen.Clin. Chem.34 (4), 715 – 718 (1988).
   PubMed Web of Science ®Google Scholar
• Nielsen MJ , NedergaardAF, SunSet al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am. J. Transl. Res. 5 (3), 303 – 315 (2013).
   PubMed Web of Science ®Google Scholar
• Leeming DJ , NielsenMJ, DaiYet al. Enzyme-linked immunosorbent serum assay specific for the 7S domain of collagen type IV (P4NP 7S): a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol. Res. 42 (5), 482 – 493 (2012).
   PubMed Web of Science ®Google Scholar
• Veidal SS , KarsdalMA, NawrockiAet al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 4, 22 (2011).
   PubMedGoogle Scholar
• Veidal SS , LarsenDV, ChenXet al. MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin. Biochem. 45 (7–8): 541 – 546 (2012).
   PubMed Web of Science ®Google Scholar
• Veidal SS , KarsdalMA, VassiliadisEet al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis – identification and validation of a novel biochemical marker assay. PLoS ONE 6 (9), e24753 (2011).
   PubMed Web of Science ®Google Scholar
• Pratta MA , SuJL, LeesnitzerMAet al. Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 14 (7), 702 – 713 (2006).
   PubMed Web of Science ®Google Scholar
• Glant TT , MikeczK, RoughleyPJ, BuzasE, PooleAR. Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans.Biochem. J.236 (1), 71 – 75 (1986).
   PubMed Web of Science ®Google Scholar
• Frisbie DD , Al-SobayilF, BillinghurstRC, KawcakCE, McIlwraithCW. Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses.Osteoarthritis Cartilage16 (10), 1196 – 1204 (2008).
   PubMed Web of Science ®Google Scholar
• Matyas JR , AtleyL, IonescuM, EyreDR, PooleAR. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis.Arthritis Rheum.50 (2), 543 – 552 (2004).
   PubMedGoogle Scholar
• Mazzuca SA , PooleAR, BrandtKD, KatzBP, LaneKA, LobanokT. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis.J. Rheumatol.33 (6), 1147 – 1151 (2006).
   PubMed Web of Science ®Google Scholar
• Poole AR , IonescuM, SwanA, DieppePA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis.J. Clin. Invest.94 (1), 25 – 33 (1994).
   PubMed Web of Science ®Google Scholar
• Rizkalla G , ReinerA, BogochE, PooleAR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease.J. Clin. Invest.90 (6), 2268 – 2277 (1992).
   PubMed Web of Science ®Google Scholar
• Sumer EU , SondergaardBC, RousseauJCet al. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 15 (2), 212 – 221 (2007).
   PubMed Web of Science ®Google Scholar
• Wang B , ChenP, JensenACet al. Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. BMC Res. Notes 2, 59 (2009).
   PubMedGoogle Scholar
• Genovese F , BarascukN, LarsenLet al. Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases. Fibrogenesis Tissue Repair 6 (1), 9 (2013).
   PubMedGoogle Scholar
• Clark AG , JordanJM, VilimVet al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum. 42 (11), 2356 – 2364 (1999).
   PubMedGoogle Scholar
• Dragomir AD , KrausVB, RennerJBet al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 10 (9), 687 – 691 (2002).
   PubMed Web of Science ®Google Scholar
• Conrozier T , SaxneT, FanCSet al. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann. Rheum. Dis. 57 (9), 527 – 532 (1998).
   PubMed Web of Science ®Google Scholar
• Fernandes FA , PucinelliML, da SilvaNP, FeldmanD. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: clinical and radiological correlation.Scand. J. Rheumatol.36 (3), 211 – 215 (2007).
   PubMed Web of Science ®Google Scholar
• Kelman A , LuiL, YaoW, KrummeA, NevittM, LaneNE. Association of higher levels of serum cartilage oligomeric matrix protein and N-telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly women.Arthritis Rheum.54 (1), 236 – 243 (2006).
   PubMedGoogle Scholar
• Erhart-Hledik JC , FavreJ, AsayJLet al. A relationship between mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in cartilage thickness after 5 years. Osteoarthritis Cartilage 20 (11), 1309 – 1315 (2012).
   PubMed Web of Science ®Google Scholar
• Skjot-Arkil H , ClausenRE, NguyenQHet al. Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm. Med. 12, 34 (2012).
   PubMed Web of Science ®Google Scholar
• Gungen G , ArdicF, FiotandikogluG, RotaS. The effect of mud pack therapy on serum YKL-40 and hsCRP levels in patients with knee osteoarthritis.Rheumatol. Int.32 (5), 1235 – 1244 (2012).
   PubMed Web of Science ®Google Scholar
• Kazakova M , BatalovA, DenevaT, MatevaN, KolarovZ, SarafianV. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis.Rheumatol. Int.33 (2), 341 – 346 (2013).
   PubMed Web of Science ®Google Scholar
• Goldberg RL . Enzyme-linked immunosorbent assay for hyaluronate using cartilage proteoglycan and an antibody to keratan sulfate.Anal. Biochem.174 (2), 448 – 458 (1988).
   PubMed Web of Science ®Google Scholar
• Bello AE , GarrettWEJr, WangHet al. Comparison of synovial fluid cartilage marker concentrations and chondral damage assessed arthroscopically in acute knee injury. Osteoarthritis Cartilage 5 (6), 419 – 426 (1997).
   PubMed Web of Science ®Google Scholar
• Elliott AL , KrausVB, LutaGet al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum. 52 (1), 105 – 111 (2005).
   PubMedGoogle Scholar
• Vincourt JB , EtienneS, GrossinLet al. Matrilin-3 switches from anti- to pro-anabolic upon integration to the extracellular matrix. Matrix Biol. 31 (5), 290 – 298 (2012).
   PubMed Web of Science ®Google Scholar
• He Y , ZhengQ, SimonsenOet al. The development and characterization of a competitive ELISA for measuring active ADAMTS-4 in a bovine cartilage ex vivo model. Matrix Biol. 32 (3–4), 143 – 151 (2013).
   PubMed Web of Science ®Google Scholar
• Green MJ , GoughAK, DevlinJet al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxf.) 42 (1), 83 – 88 (2003).
   PubMed Web of Science ®Google Scholar
• Keyszer G , LambiriI, NagelRet al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J. Rheumatol. 26 (2), 251 – 258 (1999).
   PubMed Web of Science ®Google Scholar
• Papazoglou D , PapatheodorouK, PapanasNet al. Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss? Exp. Clin. Endocrinol. Diabetes 118 (10), 730 – 734 (2010).
   PubMed Web of Science ®Google Scholar
• Niki Y , TakeuchiT, NakayamaMet al. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy. PLoS ONE 7 (5), e37447 (2012).
   PubMed Web of Science ®Google Scholar
• Mattey DL , NixonNB, DawesPT. Association of circulating levels of MMP-8 with mortality from respiratory disease in patients with rheumatoid arthritis.Arthritis Res. Ther.14 (5), R204 (2012).
   PubMed Web of Science ®Google Scholar
• Kotani T , TakeuchiT, TakaiSet al. Serum levels of matrix metalloproteinase (MMP) 9, a risk factor for acute coronary syndrome, are reduced independently of serum MMP-3 by anti-TNF-alpha antibody (infliximab) therapy in patients with rheumatoid arthritis. J. Pharmacol. Sci. 120 (1), 50 – 53 (2012).
   PubMed Web of Science ®Google Scholar
• Young-Min S , CawstonT, MarshallNet al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum. 56 (10), 3236 – 3247 (2007).
   PubMedGoogle Scholar
• Anitua E , SanchezM, de laFMet al. Relationship between investigative biomarkers and radiographic grading in patients with knee osteoarthritis. Int. J. Rheumatol. 2009, 747432 (2009).
   PubMedGoogle Scholar
• Janckila AJ , NeustadtDH, YamLT. Significance of serum TRACP in rheumatoid arthritis.J. Bone Miner. Res.23 (8), 1287 – 1295 (2008).
   PubMed Web of Science ®Google Scholar
• Chao TY , LeeSH, ChenMMet al. Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a. Clin. Chim. Acta 359 (1–2), 132 – 140 (2005).
   PubMed Web of Science ®Google Scholar
• Nenonen A , ChengS, IvaskaKKet al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J. Bone Miner. Res. 20 (10), 1804 – 1812 (2005).
   PubMed Web of Science ®Google Scholar
• Henriksen K , TankoLB, QvistP, DelmasPD, ChristiansenC, KarsdalMA. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases.Osteoporos. Int.18 (5), 681 – 685 (2007).
   PubMed Web of Science ®Google Scholar
• Munoz-Torres M , Reyes-GarciaR, Mezquita-RayaPet al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas 64 (3), 188 – 192 (2009).
   PubMed Web of Science ®Google Scholar
• dos Anjos LM , PereiraIA, d‘OrsiE, SeamanAP, BurlingameRW, MoratoEF. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis.Clin. Rheumatol.28 (2), 153 – 158 (2009).
   PubMed Web of Science ®Google Scholar
• Demoruelle MK , ParishMC, DerberLAet al. Anti-cyclic citrullinated peptide assays differ in subjects at elevated risk for rheumatoid arthritis and subjects with established disease. Arthritis Rheum. 65(9), 2243 – 2252 (2013).
   Google Scholar
• Wu R , ShovmanO, ZhangY, GilburdB, Zandman-GoddardG, ShoenfeldY. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome.Clin. Rev. Allergy Immunol.32 (1), 47 – 56 (2007).
   PubMed Web of Science ®Google Scholar
• Low JM , ChauhanAK, KietzDA, DaudU, PepmuellerPH, MooreTL. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis.J. Rheumatol.31 (9), 1829 – 1833 (2004).
   PubMed Web of Science ®Google Scholar
• Bay-Jensen AC , KarsdalMA, VassiliadisEet al. Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum. 65 (4), 972 – 980 (2013).
   PubMedGoogle Scholar
• Vassiliadis E , OliveiraCP, vares-da-SilvaMRet al. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am. J. Transl. Res. 4 (4), 403 – 414 (2012).
   PubMed Web of Science ®Google Scholar
• Catterall JB , HsuehMF, StablerTVet al. Protein modification by deamidation indicates variations in joint extracellular matrix turnover. J. Biol. Chem. 287 (7), 4640 – 4651 (2012).
   PubMed Web of Science ®Google Scholar
• Kwon SR , LimMJ, SuhCHet al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol. Int. 32 (8), 2523 – 2527 (2012).
   PubMed Web of Science ®Google Scholar
• Wang SY , LiuYY, YeHet al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J. Rheumatol. 38 (5), 821 – 827 (2011).
   PubMed Web of Science ®Google Scholar
• Daoussis D , LiossisSN, SolomouEEet al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 62 (1), 150 – 158 (2010).
   PubMedGoogle Scholar
• Voorzanger-Rousselot N , Ben-TabassiNC, GarneroP. Opposite relationships between circulating Dkk-1 and cartilage breakdown in patients with rheumatoid arthritis and knee osteoarthritis.Ann. Rheum. Dis.68 (9), 1513 – 1514 (2009).
   PubMed Web of Science ®Google Scholar
• Honsawek S , TanavaleeA, YuktanandanaP, NgarmukosS, SaetanN, TantavisutS. Dickkopf-1 (Dkk-1) in plasma and synovial fluid is inversely correlated with radiographic severity of knee osteoarthritis patients.BMC Musculoskelet. Disord.11, 257 (2010).
   PubMed Web of Science ®Google Scholar
• Liu YY , LongL, WangSYet al. Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis. Chin. Med. J. (Engl.) 123 (11), 1407 – 1412 (2010).
   PubMed Web of Science ®Google Scholar
• Gerss J , RothJ, HolzingerDet al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann. Rheum. Dis. 71 (12), 1991 – 1997 (2012).
   PubMed Web of Science ®Google Scholar
• Curtis JR , van der Helm-van MilAH, KnevelRet al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. (Hoboken) 64 (12), 1794 – 1803 (2012).
   PubMed Web of Science ®Google Scholar
• Skjot-Arkil H , SchettG, ZhangCet al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 30 (3), 371 – 379 (2012).
   PubMed Web of Science ®Google Scholar
• Scott DL , WolfeF, HuizingaTW. Rheumatoid arthritis.Lancet376 (9746), 1094 – 1108 (2010).
   PubMed Web of Science ®Google Scholar
• Grassi W , DeAR, LamannaG, CerviniC. The clinical features of rheumatoid arthritis.Eur. J. Radiol.27 (Suppl. 1), S18 – S24 (1998).
   PubMed Web of Science ®Google Scholar
• Diarra D , StolinaM, PolzerKet al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13 (2), 156 – 163 (2007).
   PubMed Web of Science ®Google Scholar
• Schett G , HayerS, ZwerinaJ, RedlichK, SmolenJS. Mechanisms of disease: the link between RANKL and arthritic bone disease.Nat. Clin. Pract. Rheumatol.1 (1), 47 – 54 (2005).
   PubMedGoogle Scholar
• Schett G , StolinaM, BolonBet al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum. 52 (10), 3192 – 3201 (2005).
   PubMedGoogle Scholar
• Willemze A , ToesRE, HuizingaTW, TrouwLA. New biomarkers in rheumatoid arthritis.Neth. J. Med.70 (9), 392 – 399 (2012).
   PubMed Web of Science ®Google Scholar
• Markatseli TE , VoulgariPV, AlamanosY, DrososAA. Prognostic factors of radiological damage in rheumatoid arthritis: a 10-year retrospective study.J. Rheumatol.38 (1), 44 – 52 (2011).
   PubMed Web of Science ®Google Scholar
• Yuasa S , YamaguchiH, NakanishiYet al. Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents. J. Med. Invest. 60 (1–2): 77 – 90 (2013).
   PubMedGoogle Scholar
• Tedesco A , D’AgostinoD, SorienteI, AmatoP, PiccoliR, SabatiniP. A new strategy for the early diagnosis of rheumatoid arthritis: a combined approach.Autoimmun. Rev.8 (3), 233 – 237 (2009).
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R , LeeJ, McCoyAet al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2 (3), 236 – 243 (2000).
   PubMedGoogle Scholar
• Nielsen SF , BojesenSE, SchnohrP, NordestgaardBG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study.Br. Med. J.345, e5244 (2012).
   PubMedGoogle Scholar
• Agrawal S , MisraR, AggarwalA. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.Clin. Rheumatol.26 (2), 201 – 204 (2007).
   PubMed Web of Science ®Google Scholar
• Jones MG , ShipleyME, HearnJP, HayFC. Specificity of rheumatoid factors in relation to the disease state in rheumatoid arthritis.Ann. Rheum. Dis.49 (10), 757 – 762 (1990).
   PubMed Web of Science ®Google Scholar
• Nell VP , MacholdKP, StammTAet al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann. Rheum. Dis. 64 (12), 1731 – 1736 (2005).
   PubMed Web of Science ®Google Scholar
• Biasiolo A , TonoN, ZaninottoMet al. Specificity of squamous cell carcinoma antigen (SCCA)-IgM detection in patients with HCV infection and rheumatoid factor seropositivity. J. Med. Virol. 85 (6), 1005 – 1008 (2013).
   PubMed Web of Science ®Google Scholar
• Bizzaro N . Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.Clin. Chem. Lab. Med.45 (2), 150 – 157 (2007).
   PubMed Web of Science ®Google Scholar
• Simon M , GirbalE, SebbagMet al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called 'antikeratin antibodies,' autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 92 (3), 1387 – 1393 (1993).
   PubMed Web of Science ®Google Scholar
• Van Venrooij WJ , van BeersJJ, PruijnGJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis.Ann. NY Acad. Sci.1143, 268 – 285 (2008).
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH , VerpoortKN, BreedveldFC, ToesRE, HuizingaTW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.Arthritis Res. Ther.7 (5), R949 – R958 (2005).
   PubMed Web of Science ®Google Scholar
• Hashimoto J , GarneroP, van derHDet al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod. Rheumatol. 19 (3), 273 – 282 (2009).
   PubMed Web of Science ®Google Scholar
• Landewe R , GeusensP, BoersMet al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum. 50 (5), 1390 – 1399 (2004).
   PubMedGoogle Scholar
• Garnero P , GineytsE, ChristgauS, FinckB, DelmasPD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.Arthritis Rheum.46 (1), 21 – 30 (2002).
   PubMedGoogle Scholar
• Fujikawa K , KawakamiA, TamaiMet al. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. J. Rheumatol. 36 (6), 1126 – 1129 (2009).
   PubMed Web of Science ®Google Scholar
• Mansson B , CareyD, AliniMet al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J. Clin. Invest. 95 (3), 1071 – 1077 (1995).
   PubMed Web of Science ®Google Scholar
• Hakala M , RisteliJ, AmanSet al. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression. Scand J. Rheumatol. 37 (2), 90 – 93 (2008).
   PubMed Web of Science ®Google Scholar
• Iba K , TakadaJ, HatakeyamaN, OzasaY, WadaT, YamashitaT. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.J. Orthop. Sci.13 (5), 438 – 441 (2008).
   PubMed Web of Science ®Google Scholar
• Sassi ML , EriksenH, RisteliLet al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26 (4), 367 – 373 (2000).
   PubMed Web of Science ®Google Scholar
• Garnero P . Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.Mol. Diagn. Ther.12 (3), 157 – 170 (2008).
   PubMed Web of Science ®Google Scholar
• Reginster JY , ColletteJ, NeuprezA, ZegelsB, DeroisyR, BruyereO. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.Bone42 (5), 832 – 836 (2008).
   PubMed Web of Science ®Google Scholar
• Vasikaran SD , GlendenningP, MorrisHA. The role of biochemical markers of bone turnover in osteoporosis management in clinical practice.Clin. Biochem. Rev.27 (3), 119 – 121 (2006).
   PubMedGoogle Scholar
• van Tuyl LH , VoskuylAE, BoersMet al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann. Rheum. Dis. 69 (9), 1623 – 1628 (2010).
   PubMed Web of Science ®Google Scholar
• Siebuhr AS , Bay-JensenAC, LeemingDJet al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res. Ther. 15 (4), R86 (2013).
   PubMed Web of Science ®Google Scholar
• Cunnane G , FitzgeraldO, BeetonC, CawstonTE, BresnihanB. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.Arthritis Rheum.44 (10), 2263 – 2274 (2001).
   PubMedGoogle Scholar
• Geusens PP , LandeweRB, GarneroPet al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 54 (6), 1772 – 1777 (2006).
   PubMedGoogle Scholar
• Verstappen SM , PooleAR, IonescuMet al. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res. Ther. 8 (1), R31 (2006).
   PubMed Web of Science ®Google Scholar
• de Vries MK , van E, I, van der Horst-BruinsmaIEet al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 61 (11), 1484 – 1490 (2009).
   PubMedGoogle Scholar
• Benhamou M , GossecL, DougadosM. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C-reactive protein.Rheumatology (Oxf.)49 (3), 536 – 541 (2010).
   PubMed Web of Science ®Google Scholar
• Londono J , Romero-SanchezMC, TorresVGet al. The association between serum levels of potential biomarkers with the presence of factors related to the clinical activity and poor prognosis in spondyloarthritis. Rev. Bras. Reumatol. 52 (4), 536 – 544 (2012).
   PubMedGoogle Scholar
• Romero-Sanchez C , RobinsonWH, TomookaBHet al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin. Rheumatol. 27 (11), 1429 – 1435 (2008).
   PubMed Web of Science ®Google Scholar
• Pedersen SJ , HetlandML, SorensenIJ, OstergaardM, NielsenHJ, JohansenJS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors.Clin. Rheumatol.29 (11), 1301 – 1309 (2010).
   PubMed Web of Science ®Google Scholar
• Pedersen SJ , SorensenIJ, GarneroPet al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors. Ann. Rheum. Dis. 70 (8), 1375 – 1381 (2011).
   PubMed Web of Science ®Google Scholar
• Mattey DL , PackhamJC, NixonNBet al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res. Ther. 14 (3), R127 (2012).
   PubMed Web of Science ®Google Scholar
• Machado P , LandeweRB, BraunJet al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann. Rheum. Dis. 71 (12), 2002 – 2005 (2012).
   PubMed Web of Science ®Google Scholar
• Wagner C , VisvanathanS, BraunJet al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann. Rheum. Dis. 71 (5), 674 – 680 (2012).
   PubMed Web of Science ®Google Scholar
• Maksymowych WP , LandeweR, Conner-SpadyBet al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 56 (6), 1846 – 1853 (2007).
   PubMedGoogle Scholar
• Jung SY , ParkMC, ParkYB, LeeSK. Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis.Yonsei Med. J.48 (2), 218 – 224 (2007).
   PubMed Web of Science ®Google Scholar
• Vosse D , LandeweR, GarneroP, van derHD, Van DerLS, GeusensP. Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis.Rheumatology (Oxf.)47 (8), 1219 – 1222 (2008).
   PubMed Web of Science ®Google Scholar
• Arends S , van d, V, KallenbergCG, BrouwerE, SpoorenbergA. Baseline predictors of response to TNF-alpha blocking therapy in ankylosing spondylitis.Curr. Opin. Rheumatol.24 (3), 290 – 298 (2012).
   PubMed Web of Science ®Google Scholar
• Arends S , SpoorenbergA, HoutmanPMet al. The effect of three years of TNFalpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res. Ther. 14 (2), R98 (2012).
   PubMed Web of Science ®Google Scholar
• Visvanathan S , van derHD, DeodharAet al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68 (2), 175 – 182 (2009).
   PubMed Web of Science ®Google Scholar
• Pedersen SJ , SorensenIJ, LambertRGet al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor alpha inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum. 63 (12), 3789 – 3800 (2011).
   PubMed Web of Science ®Google Scholar
• Bay-Jensen AC , LeemingDJ, KleyerA, VeidalSS, SchettG, KarsdalMA. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study.Rheumatol. Int.32 (11), 3565 – 3572 (2012).
   PubMed Web of Science ®Google Scholar
• Bodnar N , SzekaneczZ, ProhaszkaZet al. Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat shock protein (anti-hsp65): new biomarkers in ankylosing spondylitis. Joint Bone Spine 79 (1), 63 – 66 (2012).
   PubMed Web of Science ®Google Scholar
• Langley RG , KruegerGG, GriffithsCE. Psoriasis: epidemiology, clinical features, and quality of life.Ann. Rheum. Dis.64 (Suppl. 2), ii18 – ii23 (2005).
   PubMed Web of Science ®Google Scholar
• Zachariae H . Prevalence of joint disease in patients with psoriasis: implications for therapy.Am. J. Clin. Dermatol.4 (7), 441 – 447 (2003).
   PubMed Web of Science ®Google Scholar
• Wagner CL , VisvanathanS, ElashoffMet al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann. Rheum. Dis. 72 (1), 83 – 88 (2013).
   PubMed Web of Science ®Google Scholar
• van Kuijk AW , DeGrootJ, KoemanRCet al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS ONE5 (9), e12556 (2010).
   PubMed Web of Science ®Google Scholar
• van Kuijk AW , GerlagDM, VosKet al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann. Rheum. Dis. 68 (8), 1303 – 1309 (2009).
   PubMed Web of Science ®Google Scholar
• Chandran V , CookRJ, EdwinJet al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxf.) 49 (7), 1399 – 1405 (2010).
   PubMed Web of Science ®Google Scholar
• Gilliam BE , ChauhanAK, LowJM, MooreTL. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study.Clin. Exp. Rheumatol.26 (3), 492 – 497 (2008).
   PubMed Web of Science ®Google Scholar
• Bjornhart B , JuulA, NielsenS, ZakM, SvenningsenP, MullerK. Cartilage oligomeric matrix protein in patients with juvenile idiopathic arthritis: relation to growth and disease activity.J. Rheumatol.36 (8), 1749 – 1754 (2009).
   PubMed Web of Science ®Google Scholar
• Nakajima S , NarutoT, MiyamaeTet al. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod. Rheumatol. 19 (1), 42 – 46 (2009).
   PubMed Web of Science ®Google Scholar
• Urakami T , MankiA, InoueT, OdaM, TanakaH, MorishimaT. Clinical significance of decreased serum concentration of cartilage oligomeric matrix protein in systemic juvenile idiopathic arthritis.J. Rheumatol.33 (5), 996 – 1000 (2006).
   PubMed Web of Science ®Google Scholar
• el-Sayed ZA , SalehMT, Al-WakkadAS, SheriefLS, Nasr el-DinAM. Cartilage proteoglycan aggrecan as a predictor of joint damage in juvenile rheumatoid arthritis.East Mediterr. Health J.7 (6), 992 – 1003 (2001).
   PubMedGoogle Scholar
• Falcini F , ErminiM, BagnoliF. Bone turnover is reduced in children with juvenile rheumatoid arthritis.J. Endocrinol. Invest.21 (1), 31 – 36 (1998).
   PubMed Web of Science ®Google Scholar
• Ling XB , ParkJL, CarrollTet al. Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics 10 (24), 4415 – 4430 (2010).
   PubMed Web of Science ®Google Scholar
• Miyamae T , MalehornDE, LemsterBet al. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy. Arthritis Res. Ther. 7 (4), R746 – R755 (2005).
   PubMed Web of Science ®Google Scholar
• Cantarini L , GianiT, FioravantiAet al. Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med. J. 53 (5), 1045 – 1048 (2012).
   PubMed Web of Science ®Google Scholar
• Ling XB , MacaubasC, AlexanderHCet al. Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis. BMC Med. 10, 125 (2012).
   PubMed Web of Science ®Google Scholar
• Levalampi T , HonkanenV, LahdenneP, NieminenR, HakalaM, MoilanenE. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis.Scand. J. Rheumatol.36 (3), 189 – 193 (2007).
   PubMed Web of Science ®Google Scholar
• Visvanathan S , WagnerC, MariniJCet al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr. Rheumatol. Online J. 8, 24 (2010).
   PubMed Web of Science ®Google Scholar
• Moncrieffe H , UrsuS, HolzingerDet al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxf.) 52 (8), 1467 – 1476 (2013).
   PubMed Web of Science ®Google Scholar
• Zhen EY , BrittainIJ, LaskaDAet al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum. 58 (8), 2420 – 2431 (2008).
   PubMed Web of Science ®Google Scholar
• Sowers MF , Karvonen-GutierrezCA, YosefMet al. Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women. Osteoarthritis Cartilage 17 (12), 1609 – 1614 (2009).
   PubMed Web of Science ®Google Scholar
• Hoch JM , MattacolaCG, Medina McKeonJM, HowardJS, LattermannC. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis.Osteoarthritis Cartilage19 (12), 1396 – 1404 (2011).
   PubMed Web of Science ®Google Scholar